327 related articles for article (PubMed ID: 28708284)
1. CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.
Peipp M; Wesch D; Oberg HH; Lutz S; Muskulus A; van de Winkel JGJ; Parren PWHI; Burger R; Humpe A; Kabelitz D; Gramatzki M; Kellner C
Scand J Immunol; 2017 Oct; 86(4):196-206. PubMed ID: 28708284
[TBL] [Abstract][Full Text] [Related]
2. Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30.
Kellner C; Günther A; Humpe A; Repp R; Klausz K; Derer S; Valerius T; Ritgen M; Brüggemann M; van de Winkel JG; Parren PW; Kneba M; Gramatzki M; Peipp M
Oncoimmunology; 2016; 5(1):e1058459. PubMed ID: 26942070
[TBL] [Abstract][Full Text] [Related]
3. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
Kellner C; Maurer T; Hallack D; Repp R; van de Winkel JG; Parren PW; Valerius T; Humpe A; Gramatzki M; Peipp M
J Immunol; 2012 Nov; 189(10):5037-46. PubMed ID: 23066150
[TBL] [Abstract][Full Text] [Related]
4. Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition.
Wrobel P; Shojaei H; Schittek B; Gieseler F; Wollenberg B; Kalthoff H; Kabelitz D; Wesch D
Scand J Immunol; 2007; 66(2-3):320-8. PubMed ID: 17635809
[TBL] [Abstract][Full Text] [Related]
5. NK cell-mediated anti-leukemia cytotoxicity is enhanced using a NKG2D ligand MICA and anti-CD20 scfv chimeric protein.
Zou Y; Luo W; Guo J; Luo Q; Deng M; Lu Z; Fang Y; Zhang CC
Eur J Immunol; 2018 Oct; 48(10):1750-1763. PubMed ID: 30063799
[TBL] [Abstract][Full Text] [Related]
6. Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity.
Kellner C; Hallack D; Glorius P; Staudinger M; Mohseni Nodehi S; de Weers M; van de Winkel JG; Parren PW; Stauch M; Valerius T; Repp R; Humpe A; Gramatzki M; Peipp M
Leukemia; 2012 Apr; 26(4):830-4. PubMed ID: 22005785
[No Abstract] [Full Text] [Related]
7. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib enhances cytotoxicity of ex vivo-expanded gamma delta T cells against acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Story JY; Zoine JT; Burnham RE; Hamilton JAG; Spencer HT; Doering CB; Raikar SS
Cytotherapy; 2021 Jan; 23(1):12-24. PubMed ID: 33168453
[TBL] [Abstract][Full Text] [Related]
9. The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma.
Rothe A; Jachimowicz RD; Borchmann S; Madlener M; Keßler J; Reiners KS; Sauer M; Hansen HP; Ullrich RT; Chatterjee S; Borchmann P; Yazaki P; Koslowsky TC; Engert A; Heukamp LC; Hallek M; von Strandmann EP
Int J Cancer; 2014 Jun; 134(12):2829-40. PubMed ID: 24242212
[TBL] [Abstract][Full Text] [Related]
10. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
11. Distinct pattern of human Vdelta1 gammadelta T cells recognizing MICA.
Li J; Cui L; He W
Cell Mol Immunol; 2005 Aug; 2(4):253-8. PubMed ID: 16274622
[TBL] [Abstract][Full Text] [Related]
12. Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma.
Jachimowicz RD; Fracasso G; Yazaki PJ; Power BE; Borchmann P; Engert A; Hansen HP; Reiners KS; Marie M; von Strandmann EP; Rothe A
Mol Cancer Ther; 2011 Jun; 10(6):1036-45. PubMed ID: 21525185
[TBL] [Abstract][Full Text] [Related]
13. Activation of V gamma 9V delta 2 T cells by NKG2D.
Rincon-Orozco B; Kunzmann V; Wrobel P; Kabelitz D; Steinle A; Herrmann T
J Immunol; 2005 Aug; 175(4):2144-51. PubMed ID: 16081780
[TBL] [Abstract][Full Text] [Related]
14. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.
Zhang T; Sentman CL
Cancer Res; 2011 Mar; 71(6):2066-76. PubMed ID: 21282338
[TBL] [Abstract][Full Text] [Related]
15. CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells.
Sauer M; Schuldner M; Hoffmann N; Cetintas A; Reiners KS; Shatnyeva O; Hallek M; Hansen HP; Gasser S; von Strandmann EP
Oncogene; 2017 Feb; 36(7):933-941. PubMed ID: 27477692
[TBL] [Abstract][Full Text] [Related]
16. The histone deacetylase inhibitor SAHA simultaneously reactivates HIV-1 from latency and up-regulates NKG2D ligands sensitizing for natural killer cell cytotoxicity.
Desimio MG; Giuliani E; Doria M
Virology; 2017 Oct; 510():9-21. PubMed ID: 28689087
[TBL] [Abstract][Full Text] [Related]
17. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.
Peipp M; Derer S; Lohse S; Staudinger M; Klausz K; Valerius T; Gramatzki M; Kellner C
Oncotarget; 2015 Oct; 6(31):32075-88. PubMed ID: 26392331
[TBL] [Abstract][Full Text] [Related]
18. Decitabine Enhances Vγ9Vδ2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells
Wang Z; Wang Z; Li S; Li B; Sun L; Li H; Lin P; Wang S; Teng W; Zhou X; Ye Z
Front Immunol; 2018; 9():1239. PubMed ID: 29910819
[TBL] [Abstract][Full Text] [Related]
19. NKG2D ligand expression in Crohn's disease and NKG2D-dependent stimulation of CD8
Vadstrup K; Galsgaard ED; Jensen H; Lanier LL; Ryan JC; Chen SY; Nolan GP; Vester-Andersen MK; Pedersen JS; Gerwien J; Jensen T; Bendtsen F
Exp Mol Pathol; 2017 Aug; 103(1):56-70. PubMed ID: 28684217
[TBL] [Abstract][Full Text] [Related]
20. CMV-independent lysis of glioblastoma by ex vivo expanded/activated Vδ1+ γδ T cells.
Knight A; Arnouk H; Britt W; Gillespie GY; Cloud GA; Harkins L; Su Y; Lowdell MW; Lamb LS
PLoS One; 2013; 8(8):e68729. PubMed ID: 23950874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
